sinc
begin
decemb
numer
hospit
wuhan
china
report
increas
number
patient
pneumonia
due
infect
unknown
viru
viru
first
name
novel
corona
viru
later
chang
sever
acut
respiratori
syndrom
corona
viru
pneumonia
name
corona
viru
diseas
world
health
organ
declar
public
health
emerg
intern
concern
januari
march
viru
infect
peopl
kill
number
patient
increas
daili
urgent
need
effect
therapeut
intervent
articl
discuss
sever
therapeut
strategi
infect
first
case
unit
state
confirm
januari
qpcr
assay
sampl
patient
nasopharyng
oropharyng
swab
probe
base
genom
sequenc
releas
scientist
china
develop
radiograph
pneumonia
patient
treat
remdesivir
intraven
almost
clinic
symptom
resolv
follow
remdesivir
figur
nucleotid
analog
origin
develop
gilead
drug
ebola
viru
mechanist
inhibit
rnadepend
rna
synthetas
rdrp
complet
phase
andor
ii
clinic
therefor
gilead
work
china
sinc
februari
conduct
phase
random
doubleblind
placebocontrol
multicent
trial
determin
safeti
efficaci
remdesivir
hospit
patient
sever
treatment
design
mg
remdesivir
day
follow
mgday
day
studi
expect
complet
may
addit
antivir
nucleotid
analog
fapivir
ribavirin
undergo
clinic
trial
fapivir
drug
approv
japan
flu
treatment
chloroquin
phosphat
antimalari
drug
increas
ph
nucleu
inhibit
virushost
cell
interact
phdepend
viru
result
vitro
studi
suggest
chloroquin
activ
inhibit
anim
experi
clinic
trial
current
progress
result
preliminari
clinic
trial
show
chloroquin
phosphat
promis
effect
patient
note
report
chloroquin
may
caus
advers
reaction
ocular
disord
immun
system
disord
ear
labyrinth
disord
cardiac
disord
therefor
precaut
test
need
safe
effect
treatment
patient
abidol
broadspectrum
antivir
drug
inhibit
fusion
influenza
viru
host
cell
inhibit
viru
replic
use
preventtreat
sar
middl
east
respiratori
syndrom
mer
accord
onlin
report
abidol
concentr
rang
inhibit
duplic
also
significantli
reduc
patholog
effect
random
multicent
control
clinic
trial
wtih
abidol
patient
start
xiangya
hospit
china
regist
us
clinic
trial
lopinavirritonavir
combin
drug
mainli
use
aid
treatment
lopinavir
inhibit
viral
proteas
result
immaturenoninfecti
viru
particl
ritonavir
inhibit
degrad
lopinavir
liver
therebi
extend
lopinavir
halflif
result
vitro
studi
show
lopinavirritonavir
inhibit
replic
mer
howev
whether
inhibit
unknown
therefor
clinic
trial
use
lopinavirritonavir
treatment
launch
soon
hospit
wuhan
china
addit
sinc
darunavir
trade
name
prozek
anoth
proteas
inhibitor
use
hiv
treatment
combin
darunavir
ritonavir
could
also
potenti
treatment
especi
sinc
darunavir
approv
china
sinc
hiv
treatment
compani
cnbg
claim
februari
plasma
recov
patient
use
success
cure
critic
ill
patient
donat
plasma
hightit
antibodi
confirm
without
pathogen
viru
note
hour
posttreat
major
inflamm
symptom
decreas
significantli
increas
lymphocyt
count
blood
oxygen
satur
improv
vital
sign
also
observ
current
although
exact
underli
mechan
unknown
reason
specul
antibodi
may
bind
viru
prevent
virushost
cell
interact
therefor
prevent
infect
addit
nk
cell
immun
cell
may
also
involv
clear
viru
antibodydepend
cellmedi
cytotox
howev
potenti
risk
associ
plasma
usag
includ
pathogen
transmiss
allerg
reaction
consid
therefor
strategi
may
appli
clinic
emerg
follow
standard
procedur
hand
specif
immunoglobulin
could
better
option
treat
critic
ill
patient
infect
specif
neutral
antibodi
viral
surfac
protein
may
bind
prevent
viru
enter
host
epitheli
cell
subsequ
prevent
viru
amplif
hand
nonneutr
antibodi
may
bind
viru
activ
immun
cell
mainli
macrophag
engulf
clear
viru
howev
excess
activ
nonspecif
immun
cell
may
caus
releas
larg
number
proinflammatori
factor
lead
cytokin
storm
sepsisrel
death
therefor
nonneutr
antibodi
play
antivir
role
earli
stage
may
caus
lung
damag
later
stage
howev
usual
take
extend
period
time
gener
monoclon
antibodi
new
pathogen
use
clinic
regeneron
pharmaceut
use
velocisuit
technolog
human
mous
immun
system
rapidli
develop
innov
antibodi
treatment
viru
sepsi
strategi
shown
posit
result
clinic
trial
use
antibodi
treat
german
compani
inflarx
develop
monoclon
antibodi
human
molecul
specif
bind
inhibit
biolog
function
includ
releas
neutrophil
chemotaxi
intracellular
lysozym
antibodi
limit
excess
inflamm
without
inhibit
immun
function
clinic
trial
antibodi
underway
china
potenti
reduc
lung
damag
death
caus
sepsi
least
four
candid
vaccin
sepsi
develop
clinic
trial
promis
vaccin
candid
may
start
three
four
month
howev
usual
take
year
vaccin
becom
clinic
due
selfrenew
multidirect
differenti
capabl
mesenchym
stem
cell
differenti
produc
multifunct
cell
damag
lung
tissu
stem
cell
may
abl
replenish
bronchial
epitheli
endotheli
cell
clearanc
viral
infect
may
also
stabil
pulmonari
micro
blood
vessel
alveolar
epitheli
cell
barrier
effect
could
enhanc
patient
immun
allevi
pneumonia
prevent
secondari
infect
februari
project
approv
treatment
china
anoth
one
appli
us
food
drug
administr
fda
emerg
clinic
trial
treatment
option
also
agenda
search
word
china
clinic
trial
registri
http
wwwchictrorgcn
reveal
clinic
trial
regist
platform
march
dozen
clinic
trial
also
regist
intern
platform
clinic
trial
http
clinicaltrialsgov
recent
key
target
therapeut
intervent
cryoem
structur
cov
spike
protein
trimer
form
elucid
may
contribut
therapeut
design
near
current
remdesivir
appear
promis
drug
treatment
pneumonia
caus
pneumonia
mani
agent
strategi
test
treatment
patient
howev
doubleblind
random
control
trial
requir
investig
safeti
efficaci
recent
diseas
due
infect
new
coronaviru
caus
pandem
necessit
develop
effect
therapeut
mani
clinic
trial
initi
worldwid
potenti
therapeut
includ
nucleotid
phosphat
abidol
stem
cell
among
import
strategi
develop
